We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Vaccitech PLC | NASDAQ:VACC | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 5.00 | 4.75 | 4.76 | 0 | 01:00:00 |
“2021 was a pivotal year for Vaccitech during which we achieved a number of strategic, operational, and financial objectives, advanced multiple immunotherapeutic and prophylactic candidates in clinical development and strengthened and expanded our T cell activating discovery engine platform via the acquisition of Avidea Technologies,” commented Bill Enright, Vaccitech’s CEO. “All of this progress puts us in a strong position to deliver on our long-term plans. We anticipate that 2022 will be a year where we continue to advance our product pipeline with key data readouts in several programs. We look forward to reporting on these developments throughout the year.”
2021 and Recent Corporate Developments
Upcoming Milestones
Full Year 2021 Financial Highlights:
About Vaccitech
Vaccitech (“the Company”) is a clinical-stage biopharmaceutical company engaged in the discovery and development primarily of novel immunotherapies for the treatment of chronic infectious diseases, cancer and other diseases where the T cell arm of the immune system is believed to play an important role. The company’s proprietary platforms include modified simian adenoviral vectors (ChAdOx1 and ChAdOx2), other viral vectors including the well-validated Modified vaccinia Ankara (MVA) and synthetic nano-particle technologies (SNAPvax™ and Syntholytic™). The combination of different technologies in a mix and match approach (heterologous prime-boost) consistently generates significantly higher magnitudes of T cells compared with other technologies and approaches. The Company has a broad pipeline of both clinical and preclinical stage therapeutic programs to treat solid tumors, chronic viral infections, as well as a few prophylactic viral vaccine programs. Vaccitech co-invented a COVID-19 vaccine with the University of Oxford, now approved for use in many territories and exclusively licensed worldwide to AstraZeneca through Oxford University Innovation, or OUI. Vaccitech is entitled to receive a share of all milestone and royalty income received by OUI from AstraZeneca.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding the timing and advancement of the Company’s programs, including the clinical trials of VTP-200, VTP-300, VTP-600, and VTP-850, the expected benefits of the acquisition of Avidea Technologies, the benefits of the collaboration with Arbutus BioPharma Corporation and the Company’s cash runway The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management’s current expectations and beliefs and are subject to numerous risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation: the success, cost and timing of the Company’s product development activities and planned and ongoing clinical trials, the Company’s ability to execute on its strategy, regulatory developments, the Company’s ability to fund its operations, global economic uncertainty and the impact that the current ongoing COVID-19 pandemic will have on the Company’s clinical trials, preclinical studies and access to capital and other risks identified in the Company’s filings with the Securities and Exchange Commission (the “SEC”), including its Quarterly Report on Form 10-Q for the third quarter of 2021 and subsequent filings with the SEC. The Company cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. The Company expressly disclaims any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements.
VACCITECH PLCCONSOLIDATED BALANCE SHEETS(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)
As of December 31, 2021 | As of December 31, 2020 | |||||||||
Assets | ||||||||||
Current assets: | ||||||||||
Cash and cash equivalents | $ | 214,054 | $ | 43,266 | ||||||
Accounts receivable | 20 | 518 | ||||||||
Research and development incentives receivable | 6,229 | 2,708 | ||||||||
Prepaid expenses and other current assets | 6,462 | 1,409 | ||||||||
Total current assets | 226,765 | 47,901 | ||||||||
Goodwill | 12,630 | - | ||||||||
Property and equipment, net | 1,829 | 629 | ||||||||
Intangible assets, net | 31,430 | - | ||||||||
Right of use assets, net | 7,257 | 2,136 | ||||||||
Other assets | 804 | - | ||||||||
Total assets | $ | 280,715 | $ | 50,666 | ||||||
Liabilities, Redeemable Convertible Preferred Shares And Shareholders’ Equity (Deficit) | ||||||||||
Current liabilities: | ||||||||||
Accounts payable | $ | 2,419 | $ | 4,667 | ||||||
Accrued expenses and other current liabilities | 7,875 | 2,537 | ||||||||
Deferred revenue | 182 | 245 | ||||||||
Current portion of lease liability | 523 | 192 | ||||||||
Debt | 159 | - | ||||||||
Total current liabilities | 11,158 | 7,641 | ||||||||
Convertible loan notes – non current | - | 44,700 | ||||||||
Lease liability – non current | 6,540 | 1,472 | ||||||||
Contingent consideration | 2,371 | - | ||||||||
Deferred tax liability, net | 8,084 | - | ||||||||
Total liabilities | 28,153 | 53,813 | ||||||||
Commitments and contingencies | ||||||||||
Series A redeemable convertible preferred shares; £0.10 nominal value; no shares issued and outstanding; (December 31,2020: issued and outstanding: 22,065) | - | 33,765 | ||||||||
Series B redeemable convertible preferred shares (Series B shares); £0.10 nominal value; no shares issued and outstanding; (December 31, 2020: issued and outstanding: no shares issued or outstanding) | - | - | ||||||||
Shareholders’ equity (deficit): | ||||||||||
Ordinary shares, £0.000025 nominal value; 37,188,730 shares authorized, issued and outstanding (December 31, 2020: authorized, issued and outstanding: 7,960,458) | 1 | 01 | ||||||||
Deferred A shares, £1 nominal value; 63,443 shares authorized, issued and outstanding (December 31, 2020: no shares issued or outstanding) | 86 | - | ||||||||
Deferred B shares, £0.01 nominal value; 570,987 shares authorized, issued and outstanding (December 31, 2020: no shares issued or outstanding) | 8 | - | ||||||||
Deferred C shares, £0.000007 nominal value, 27,828,231 shares authorized, issued and outstanding (December 31, 2020: authorized, issued and outstanding: 7,960,458) | 01 | 01 | ||||||||
Additional paid-in capital | 369,103 | 21,660 | ||||||||
Accumulated deficit | (108,585 | ) | (57,720 | ) | ||||||
Accumulated other comprehensive loss – foreign currency translation adjustments | (8,488 | ) | (1,243 | ) | ||||||
Noncontrolling interest | 437 | 391 | ||||||||
Total shareholders’ equity/(deficit) | 252,562 | (36,912 | ) | |||||||
Total liabilities, redeemable convertible preferred shares and shareholders’ equity | $ | 280,715 | $ | 50,666 |
1 Indicates amount less than thousand
VACCITECH PLCCONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS(IN THOUSANDS, EXCEPT NUMBER OF SHARES AND PER SHARE AMOUNTS)
Year ended December 31, 2021 | Year ended December 31, 2020 | ||||||||
License revenue | $ | 63 | $ | 2,553 | |||||
Service revenue | 21 | 405 | |||||||
Research grants and contracts | 184 | 1,863 | |||||||
Total revenue | 268 | 4,821 | |||||||
Operating expenses | |||||||||
Research and development | 20,371 | 14,387 | |||||||
General and administrative | 25,118 | 10,480 | |||||||
Total operating expenses | 45,489 | 24,867 | |||||||
Loss from operations | (45,221 | ) | (20,046 | ) | |||||
Other income (expense): | |||||||||
Change in fair value of derivatives | 5,994 | 2,039 | |||||||
Unrealized foreign exchange gain on convertible loan notes | 209 | 448 | |||||||
Loss on extinguishment of convertible loan notes | (13,789 | ) | - | ||||||
Interest expense | (2,668 | ) | (3,600 | ) | |||||
Interest income | 2 | 01 | |||||||
Research and development incentives | 4,001 | 3,279 | |||||||
Other income, net | 332 | 42 | |||||||
Total other (expense) income | (5,919 | ) | 2,208 | ||||||
Tax benefit (expense) | 28 | (95 | ) | ||||||
Net loss | (51,112 | ) | (17,933 | ) | |||||
Net loss attributable to noncontrolling interest | 247 | 227 | |||||||
Net loss attributable to Vaccitech shareholders | $ | (50,865 | ) | $ | (17,706 | ) | |||
Weighted-average ordinary shares outstanding, basic and diluted | 25,894,375 | 7,904,529 | |||||||
Net loss per share attributable to ordinary shareholders, basic and diluted | $ | (1.96 | ) | $ | (2.24 | ) | |||
Net loss | $ | (51,112 | ) | $ | (17,933 | ) | |||
Other comprehensive loss – foreign currency translation adjustments | (7,248 | ) | (776 | ) | |||||
Comprehensive loss | (58,360 | ) | (18,709 | ) | |||||
Comprehensive loss attributable to noncontrolling interest | 250 | 227 | |||||||
Comprehensive loss attributable to Vaccitech shareholders | $ | (58,110 | ) | $ | (18,482 | ) |
Investors:Vaccitech Investor Relationsir@vaccitech.co.uk
Vaccitech Media Contacts:
Katja Stout, Scius Communications (EU)Direct: +44 (0) 7789435990Email: katja@sciuscommunications.com
Robert Flamm, Ph.D. (US) / Katie Larch (US)Email: rflamm@burnsmc.com / klarch@burnsmc.com
Karim Saleh, VaccitechEmail: karim.saleh@vaccitech.co.uk
1 Year Vaccitech Chart |
1 Month Vaccitech Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions